Shikonin induces apoptotic cell death via regulation of p53 and Nrf2 in AGS human stomach carcinoma cells

Hyeonseok Ko, Sun Joong Kim, So Hee Shim, Hyo-Ihl Chang, Chang Hoon Ha

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Shikonin, which derives from Lithospermum erythrorhizon, has been traditionally used against a variety of diseases, including cancer, in Eastern Asia. Here we determined that shikonin inhibits proliferation of gastric cancer cells by inducing apoptosis. Shikonin’s biological activity was validated by observing cell viability, caspase 3 activity, reactive oxygen species (ROS) generation, and apoptotic marker expressions in AGS stomach cancer cells. The concentration range of shikonin was 35-250 nM with the incubation time of 6 h. Protein levels of Nrf2 and p53 were evaluated by western blotting and confirmed by real-time PCR. Our results revealed that shikonin induced the generation of ROS as well as caspase 3-dependent apoptosis. c-Jun-N-terminal kinases (JNK) activity was significantly elevated in shikonin-treated cells, thereby linking JNK to apoptosis. Furthermore, our results revealed that shikonin induced p53 expression but repressed Nrf2 expression. Moreover, our results suggested that there may be a co-regulation between p53 and Nrf2, in which transfection with siNrf2 induced the p53 expression. We demonstrated for the first time that shikonin activated cell apoptosis in AGS cells via caspase 3- and JNK-dependent pathways, as well as through the p53-Nrf2 mediated signal pathway. Our study validates in partly the contribution of shikonin as a new therapeutic approaches/ agent for cancer chemotherapy.

Original languageEnglish
Pages (from-to)501-509
Number of pages9
JournalBiomolecules and Therapeutics
Volume24
Issue number5
DOIs
Publication statusPublished - 2016 Sep 1

Fingerprint

Cell death
Stomach
Cell Death
Cells
Carcinoma
JNK Mitogen-Activated Protein Kinases
Caspase 3
Apoptosis
Stomach Neoplasms
Reactive Oxygen Species
Lithospermum
Far East
shikonin
Bioactivity
Antineoplastic Agents
Transfection
Real-Time Polymerase Chain Reaction
Signal Transduction
Cell Survival
Western Blotting

Keywords

  • Apoptosis
  • JNK
  • Nrf2
  • p53
  • ROS
  • Shikonin

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cite this

Shikonin induces apoptotic cell death via regulation of p53 and Nrf2 in AGS human stomach carcinoma cells. / Ko, Hyeonseok; Kim, Sun Joong; Shim, So Hee; Chang, Hyo-Ihl; Ha, Chang Hoon.

In: Biomolecules and Therapeutics, Vol. 24, No. 5, 01.09.2016, p. 501-509.

Research output: Contribution to journalArticle

Ko, Hyeonseok ; Kim, Sun Joong ; Shim, So Hee ; Chang, Hyo-Ihl ; Ha, Chang Hoon. / Shikonin induces apoptotic cell death via regulation of p53 and Nrf2 in AGS human stomach carcinoma cells. In: Biomolecules and Therapeutics. 2016 ; Vol. 24, No. 5. pp. 501-509.
@article{c6f3f0d0040b4991bd7ca64b0bbe75ff,
title = "Shikonin induces apoptotic cell death via regulation of p53 and Nrf2 in AGS human stomach carcinoma cells",
abstract = "Shikonin, which derives from Lithospermum erythrorhizon, has been traditionally used against a variety of diseases, including cancer, in Eastern Asia. Here we determined that shikonin inhibits proliferation of gastric cancer cells by inducing apoptosis. Shikonin’s biological activity was validated by observing cell viability, caspase 3 activity, reactive oxygen species (ROS) generation, and apoptotic marker expressions in AGS stomach cancer cells. The concentration range of shikonin was 35-250 nM with the incubation time of 6 h. Protein levels of Nrf2 and p53 were evaluated by western blotting and confirmed by real-time PCR. Our results revealed that shikonin induced the generation of ROS as well as caspase 3-dependent apoptosis. c-Jun-N-terminal kinases (JNK) activity was significantly elevated in shikonin-treated cells, thereby linking JNK to apoptosis. Furthermore, our results revealed that shikonin induced p53 expression but repressed Nrf2 expression. Moreover, our results suggested that there may be a co-regulation between p53 and Nrf2, in which transfection with siNrf2 induced the p53 expression. We demonstrated for the first time that shikonin activated cell apoptosis in AGS cells via caspase 3- and JNK-dependent pathways, as well as through the p53-Nrf2 mediated signal pathway. Our study validates in partly the contribution of shikonin as a new therapeutic approaches/ agent for cancer chemotherapy.",
keywords = "Apoptosis, JNK, Nrf2, p53, ROS, Shikonin",
author = "Hyeonseok Ko and Kim, {Sun Joong} and Shim, {So Hee} and Hyo-Ihl Chang and Ha, {Chang Hoon}",
year = "2016",
month = "9",
day = "1",
doi = "10.4062/biomolther.2016.008",
language = "English",
volume = "24",
pages = "501--509",
journal = "Biomolecules and Therapeutics",
issn = "1976-9148",
publisher = "Korean Society of Applied Pharmacology",
number = "5",

}

TY - JOUR

T1 - Shikonin induces apoptotic cell death via regulation of p53 and Nrf2 in AGS human stomach carcinoma cells

AU - Ko, Hyeonseok

AU - Kim, Sun Joong

AU - Shim, So Hee

AU - Chang, Hyo-Ihl

AU - Ha, Chang Hoon

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Shikonin, which derives from Lithospermum erythrorhizon, has been traditionally used against a variety of diseases, including cancer, in Eastern Asia. Here we determined that shikonin inhibits proliferation of gastric cancer cells by inducing apoptosis. Shikonin’s biological activity was validated by observing cell viability, caspase 3 activity, reactive oxygen species (ROS) generation, and apoptotic marker expressions in AGS stomach cancer cells. The concentration range of shikonin was 35-250 nM with the incubation time of 6 h. Protein levels of Nrf2 and p53 were evaluated by western blotting and confirmed by real-time PCR. Our results revealed that shikonin induced the generation of ROS as well as caspase 3-dependent apoptosis. c-Jun-N-terminal kinases (JNK) activity was significantly elevated in shikonin-treated cells, thereby linking JNK to apoptosis. Furthermore, our results revealed that shikonin induced p53 expression but repressed Nrf2 expression. Moreover, our results suggested that there may be a co-regulation between p53 and Nrf2, in which transfection with siNrf2 induced the p53 expression. We demonstrated for the first time that shikonin activated cell apoptosis in AGS cells via caspase 3- and JNK-dependent pathways, as well as through the p53-Nrf2 mediated signal pathway. Our study validates in partly the contribution of shikonin as a new therapeutic approaches/ agent for cancer chemotherapy.

AB - Shikonin, which derives from Lithospermum erythrorhizon, has been traditionally used against a variety of diseases, including cancer, in Eastern Asia. Here we determined that shikonin inhibits proliferation of gastric cancer cells by inducing apoptosis. Shikonin’s biological activity was validated by observing cell viability, caspase 3 activity, reactive oxygen species (ROS) generation, and apoptotic marker expressions in AGS stomach cancer cells. The concentration range of shikonin was 35-250 nM with the incubation time of 6 h. Protein levels of Nrf2 and p53 were evaluated by western blotting and confirmed by real-time PCR. Our results revealed that shikonin induced the generation of ROS as well as caspase 3-dependent apoptosis. c-Jun-N-terminal kinases (JNK) activity was significantly elevated in shikonin-treated cells, thereby linking JNK to apoptosis. Furthermore, our results revealed that shikonin induced p53 expression but repressed Nrf2 expression. Moreover, our results suggested that there may be a co-regulation between p53 and Nrf2, in which transfection with siNrf2 induced the p53 expression. We demonstrated for the first time that shikonin activated cell apoptosis in AGS cells via caspase 3- and JNK-dependent pathways, as well as through the p53-Nrf2 mediated signal pathway. Our study validates in partly the contribution of shikonin as a new therapeutic approaches/ agent for cancer chemotherapy.

KW - Apoptosis

KW - JNK

KW - Nrf2

KW - p53

KW - ROS

KW - Shikonin

UR - http://www.scopus.com/inward/record.url?scp=84988360201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988360201&partnerID=8YFLogxK

U2 - 10.4062/biomolther.2016.008

DO - 10.4062/biomolther.2016.008

M3 - Article

AN - SCOPUS:84988360201

VL - 24

SP - 501

EP - 509

JO - Biomolecules and Therapeutics

JF - Biomolecules and Therapeutics

SN - 1976-9148

IS - 5

ER -